Improving Molecular Subtypes and Prognosis of Pancreatic Cancer Through Multi Group Analysis and Machine Learning

Overview

Journal Discov Oncol

Publisher Springer

Date 2025 Jan 28

PMID 39873820

Authors

Xue-Jian Zhang

Fang-Fang Lin

Ya-Qing Wen

Kun-Ping Guan

Affiliations

Soon will be listed here.

Abstract

Background: Pancreatic cancer (PAC) has a complex tumor immune microenvironment, and currently, there is a lack of accurate personalized treatment. Establishing a novel consensus machine learning driven signature (CMLS) that offers a unique predictive model and possible treatment targets for this condition was the goal of this study.

Methods: This study integrated multiple omics data of PAC patients, applied ten clustering techniques and ten machine learning approaches to construct molecular subtypes for PAC, and created a new CMLS.

Results: Using multi-omics clustering, we discovered two cancer subtypes (CSs) associated with prognosis, among which CS1 exhibited poor prognostic outcomes. Subsequently, 13 central genes were identified through screening, constituting CMLS with a significant prognostic ability. The low CMLS group had a better prognosis and was more likely to possess a "hot" tumor phenotype. The prognosis for the high CMLS group was dismal. Still, the tumor mutation burden (TMB) and tumor neoantigen burden (TNB) levels in this group of patients were higher than in the low CMLS group, which were more favorable for immune therapy response.

Conclusion: This study emphasizes that CMLS provides a beneficial instrument for early prediction of patient prognosis and screening of probable patients appropriate for immunotherapy and has broad implications for clinical practice.

References

Hoshida Y . Nearest template prediction: a single-sample-based flexible class prediction with confidence assessment. PLoS One. 2010; 5(11):e15543. PMC: 2990751. DOI: 10.1371/journal.pone.0015543. View

Tempero M . Santa, Can You Hear Me?. J Natl Compr Canc Netw. 2019; 17(12):1455. DOI: 10.6004/jnccn.2019.0060. View

Vincent L, Guardiola B, Tsouderos Y, Canet E . Mediator: who's to blame?. Lancet. 2011; 377(9782):2003. DOI: 10.1016/S0140-6736(11)60861-1. View

Imamura T, Ashida R, Ohshima K, Uesaka K, Sugiura T, Ohgi K . Characterization of pancreatic cancer with ultra-low tumor mutational burden. Sci Rep. 2023; 13(1):4359. PMC: 10020557. DOI: 10.1038/s41598-023-31579-8. View

Zhang H, Luo Y, Wu W, Zhang L, Wang Z, Dai Z . The molecular feature of macrophages in tumor immune microenvironment of glioma patients. Comput Struct Biotechnol J. 2021; 19:4603-4618. PMC: 8383063. DOI: 10.1016/j.csbj.2021.08.019. View

Balli D, Rech A, Stanger B, Vonderheide R . Immune Cytolytic Activity Stratifies Molecular Subsets of Human Pancreatic Cancer. Clin Cancer Res. 2016; 23(12):3129-3138. DOI: 10.1158/1078-0432.CCR-16-2128. View

Chu G, Ji X, Wang Y, Niu H . Integrated multiomics analysis and machine learning refine molecular subtypes and prognosis for muscle-invasive urothelial cancer. Mol Ther Nucleic Acids. 2023; 33:110-126. PMC: 10336357. DOI: 10.1016/j.omtn.2023.06.001. View

Reames B, Rocha F . Early Recurrence Following Resection of Distal Cholangiocarcinoma: A New Tool for the Toolbox. Ann Surg Oncol. 2021; 28(8):4069-4071. DOI: 10.1245/s10434-021-09961-5. View

Royal R, Levy C, Turner K, Mathur A, Hughes M, Kammula U . Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother. 2010; 33(8):828-33. PMC: 7322622. DOI: 10.1097/CJI.0b013e3181eec14c. View

Ma X, Guan C, Chen R, Wang Y, Feng S, Wang R . Pathological and molecular examinations of postmortem testis biopsies reveal SARS-CoV-2 infection in the testis and spermatogenesis damage in COVID-19 patients. Cell Mol Immunol. 2020; 18(2):487-489. PMC: 7734388. DOI: 10.1038/s41423-020-00604-5. View

Vincent A, Herman J, Schulick R, Hruban R, Goggins M . Pancreatic cancer. Lancet. 2011; 378(9791):607-20. PMC: 3062508. DOI: 10.1016/S0140-6736(10)62307-0. View

Heinrich S, Lang H . Neoadjuvant Therapy of Pancreatic Cancer: Definitions and Benefits. Int J Mol Sci. 2017; 18(8). PMC: 5578014. DOI: 10.3390/ijms18081622. View

10.

Liu B, Xie Y, Zhang J, Zeng S, Li J, Tao Q . SERPINB5 promotes colorectal cancer invasion and migration by promoting EMT and angiogenesis via the TNF-α/NF-κB pathway. Int Immunopharmacol. 2024; 131:111759. DOI: 10.1016/j.intimp.2024.111759. View

10.

Liu K, Liu B, Zhang Y, Wu Q, Zhong M, Shang L . Building an ensemble learning model for gastric cancer cell line classification via rapid raman spectroscopy. Comput Struct Biotechnol J. 2023; 21:802-811. PMC: 9842960. DOI: 10.1016/j.csbj.2022.12.050. View

11.

Tempero M . NCCN Guidelines Updates: Pancreatic Cancer. J Natl Compr Canc Netw. 2019; 17(5.5):603-605. DOI: 10.6004/jnccn.2019.5007. View

11.

Pisarenka S, Meyer N, Xiao X, Goodfellow R, Nester C, Zhang Y . Modeling C3 glomerulopathies: C3 convertase regulation on an extracellular matrix surface. Front Immunol. 2023; 13:1073802. PMC: 9947773. DOI: 10.3389/fimmu.2022.1073802. View

12.

Chu Z, Zhang B, Zhou X, Yuan H, Gao C, Liu L . A DNA/RNA heteroduplex oligonucleotide coupling asparagine depletion restricts FGFR2 fusion-driven intrahepatic cholangiocarcinoma. Mol Ther Nucleic Acids. 2023; 34:102047. PMC: 10589379. DOI: 10.1016/j.omtn.2023.102047. View

12.

Lu X, Meng J, Zhou Y, Jiang L, Yan F . MOVICS: an R package for multi-omics integration and visualization in cancer subtyping. Bioinformatics. 2020; 36(22-23):5539-5541. DOI: 10.1093/bioinformatics/btaa1018. View

13.

Kamisawa T, Wood L, Itoi T, Takaori K . Pancreatic cancer. Lancet. 2016; 388(10039):73-85. DOI: 10.1016/S0140-6736(16)00141-0. View

13.

Jia L, Yue M, Wang Y, Ye X, Zou Y, Zhang A . Trajectories of De Ritis ratio with risk of hepatocellular carcinoma and liver-related mortality following direct-acting antivirals for HCV: a retrospective longitudinal study up to 10 years. Carcinogenesis. 2022; 43(12):1190-1197. DOI: 10.1093/carcin/bgac094. View